Search

everythinglearnresearchcommunity

for

Search:↓

User started treatment with Fin and Min in 2022, added stemoxydine, and considering dut. They are unsure about microneedling due to scarring concerns.

The conversation is about seeking updates on new hair loss treatments, specifically mentioning scube3 and GT20029, with one person mentioning HMI_115 as showing promising results.

A 23-year-old male experienced initial success with finasteride, topical minoxidil, and ketoconazole for hair loss, but persistent shedding and scalp issues led him to switch to dutasteride without improvement. Users suggest stress management, addressing potential seborrheic dermatitis, and patience with the treatment process.

Ketoconazole shampoo does not significantly reduce systemic or scalp DHT levels and is mainly used for its anti-fungal and anti-inflammatory effects. It is not a replacement for finasteride, which is recommended by some users despite concerns about side effects.

2% fucoidan alleviated AGA symptoms, promoted hair growth, and increased hair density in mice. Fucoidan is considered safe for humans as a supplement and topical skincare product, with potential therapeutic effects against AGA.

A user is experiencing temple hair recession and is seeking alternatives to finasteride. They are considering castor oil, coconut oil, and derma rolling, and have seen some improvement with Zenegen.

Topical finasteride that doesn't penetrate the skin could potentially treat hair loss without side effects. Current challenges include finding a formulation that remains on the scalp without increasing blood levels.

KX-826 is undergoing Phase III trials in China as a potential treatment for male pattern baldness, with some users considering it as an alternative or addition to finasteride and dutasteride. Opinions on its effectiveness vary, with some users reporting positive results and others finding it expensive and ineffective.

A study that outlines the full model for androgenic alopecia (AGA) which links DHT to cellular senescence in dermal papilla cells, and suggests black chokeberry as a source of cyanidin 3-O-arabinoside polyphenol with potential anti-oxidant properties that could reverse this process. The post encourages reaching out to experts in anti-aging and longevity to research treatments involving the polyphenol.

The user is using RU58841 for hair regrowth on the temples and is considering adding minoxidil. They are questioning the potential for vellus hairs to develop into fuller hair and the possibility of reactivating dormant follicles.

The conversation is about identifying the vehicle used in the Breezula (clascoterone) trial for hair loss. No specific treatments were mentioned.

The conversation is about compounding topical cyclosporine for hair loss, suggesting it needs an oil base like castor oil. The user seeks tips or tricks for the process.

PP405 shows potential for hair growth by increasing terminal hair and converting vellus hairs, but results are modest and more waiting is needed. It complements existing treatments like minoxidil and finasteride, but won't replace them.

Biotin can cause cystic acne for some users, and it's advised to stop using it if this occurs. For hair loss, finasteride and dutasteride are recommended, but a dermatologist should be consulted.

Rapamycin and metformin may have hair regeneration properties. Specific treatments discussed include Minoxidil, finasteride, and RU58841.

The conversation is optimistic about future hair loss treatments, highlighting Veradermics, Breezula, and PP405 as promising options expected by 2027-2028. The user expresses hope that these developments will prevent future generations from experiencing the same struggles with hair loss.

OrganTech is working on regenerating hair and teeth, with positive results in mice, but skepticism remains about progress for humans. Users express frustration over the lack of advancements in human hair loss treatments, despite ongoing research and trials.

Hair care products for those using minox, keto, fin, and microneedling are discussed. Nizoral 2%, Revita shampoo, Nioxin system 2, Aveda thickening tonic, Hanz De Fuko Claymation, and Morrocanoil Texture Clay are mentioned as options.

A user shared progress photos showing hair regrowth using 5% minoxidil foam, microneedling, and 2% ketoconazole. They also started taking multivitamins and are considering adding finasteride.

The user is using RU58841 twice daily, dutasteride 0.5mg every two days, dutasteride mesotherapy every three months, and 20mg oral minoxidil daily. Other users suggest this regimen is excessive and recommend adding microneedling and ketoconazole shampoo.

A Phase II clinical trial for TDM-105795 has started recruiting in the US, and it might be a promising treatment for hair loss. Many hair loss drugs, including this one, originate from China.

Dutasteride mesotherapy showed increased hair density and diameter without reducing serum DHT levels in a small study. However, the sample size was too small to make definitive claims about its efficacy.

KX-826 is undergoing trials for hair loss treatment, showing similar effectiveness between 0.5% and 1.0% dosages, with mild side effects compared to finasteride. Users discuss combining KX-826 with other treatments like minoxidil and clascoterone for better results.

The conversation discusses hair loss treatments, specifically using topical minoxidil, oral finasteride, ketoconazole, and derma stamping. Users share their experiences, with one noting improved scalp health and slight regrowth, while another considers switching treatments due to lack of progress.

The user visited a trichologist due to ineffective topical finasteride treatment for hair loss. The trichologist recommended a new regimen including a two-month course of locoidon (cortisone 0.1%), followed by a solution containing minoxidil, hydrocortisone butirrate, estrone, progesterone, tocopherol acetate, trichosol, and transcutol.

Topical saw palmetto is discussed as a mild anti-androgen for hair growth, with some users combining it with other treatments like spironolactone and ketoconazole shampoo. Users share mixed experiences, with some not noticing regrowth and others hopeful for positive results.

Verteporfin human clinical trials for hair loss may start in 2025. Additional resources and presentations are available for more information.

The conversation discusses a user experiencing short, curly, wiry hair above and behind the ears, linking it to pattern baldness. The user suggests starting treatment early but personally chose not to pursue treatments like Minoxidil, finasteride, or RU58841 due to the hassle.

PP405 shows initial promise for treating androgenetic alopecia, with safety confirmed in early trials, but skepticism remains due to limited data. Further trials are needed to determine its true efficacy and potential market impact.

PTD-DBM is a Korean-developed treatment for hair loss, with limited information available and some users testing it personally. A user purchased PTD-DBM for $115 and plans to test it on their temples, but its effectiveness and authenticity remain uncertain.